August 21-23, 2018

Boston, MA

2016 Speakers

Expand/Collapse

Yvonne Will
ATS Fellow & Head In Vitro Discovery Toxicology
Pfizer

Dr Yvonne Will was born and raised in Germany where she conducted her undergraduate studies in Human Nutrition at the University of Bonn, while working as a full time position in the Department of Equine Exercise Physiology. In 1992, Dr Will conducted an internship at the College of Veterinary Medicine at Oregon State University, where she enrolled the same year to obtain her MS degree. Her work was focused on the bioremediation of explosives using ruminant bacteria and analytical chemistry approaches. In 2000 Dr  Will obtained her PhD in Biochemsitry and Biophysics from Oregon State University, where her thesis  focused on the relationships between glutathione deficiency and cellular and mitochondrial function/dysfunction. During her years at the biotechnology company MitoKor, San Diego (2000-2003) she was involved in drug discovery aimed on improving mitochondrial function or preventing mitochondrial dysfunction in obesity, diabetes, and CNS related diseases. From 2003 until 2007, Dr Will was a group leader in Drug Safety at Pfizer La Jolla, pioneering a screening paradigm for drug induced mitochondrial toxicity, supporting many therapeutic areas. This platform has been adapted throughout all major pharmaceutical companies. During that time she also held an adjunct faculty position at San Diego State University in the Toxicology program where she conducted lectures, taught laboratory courses and mentored MS students. In the fall of 2007 Dr Will transferred to Pfizer Groton to lead a group of scientists in the Compound Safety Prediction Group within Medicinal Chemistry. This group was set out to conduct in vitro safety assessment as early as possible within the drug discovery process to reduce late stage attrition. Dr Will’s group has pioneered many new technologies throughout the years. Dr Will has published a book on drug induced mitochondrial toxicity is currently on a new book on drug discovery toxicology. Dr Will has given many national and international lectures, conducted workshops and seminars and continues to publish numerous papers each year in peer reviewed journals, including a book on “Drug Induced Mitochondrial Toxicity” in 2008 and a book on “Drug Discovery Toxicology” in 2016. In 2012, Dr Will was honored with the Connecticut Technology Council’s Woman Research Innovation and Leadership Award. Dr Will’s passion is to develop young scientists through external influence such as publications and participations in national meetings. In September of 2014, Dr Will became the Head of Science and Technology for Drug Safety within Pfizer. As such she works on strategy as well as innovation and developing the next generation of scientists through a postdoctoral program as well as mentoring efforts. In 2015 Dr Will became  a Fellow of the Academy of Toxicological Sciences. In September of 2016, in addition to her role as the Science and Technology Strategy Lead, also was appointed to lead the Drug discovery Toxicology Efforts for Drug Safety, Pfizer.

Day One

Monday, August 28, 2017

12.15 | Panel Discussion: Development of Complex In Vitro Models for Preclinical Efficacy Testing

Frank Sistare
Scientific Associate Vice President, Safety Assessment & Laboratory Animal Resources
Merck and Co. Inc.

Frank serves presently as Scientific Associate Vice President beginning in January 2016 within Safety Assessment and Laboratory Animal Resources at Merck Research Laboratories. He served previously for 12 years as Executive Director and then Associate Vice President of the Department of Investigative Laboratory Sciences responsible for genetic toxicology assessments and molecular carcinogenesis investigations; for toxicokinetic support; for investigative toxicology research and support for safety lead optimization; for incorporating new in vitro and in vivo safety models and technologies including genomics, proteomics, metabonomics, and genetically engineered animal models; and for providing new translational safety biomarker development support for drug development. He served previously for 15 years in several leadership and management positions with the laboratory research component of the Food and Drug Administration’s Center for Drug Evaluation and Research.  Dr. Sistare is a retired Captain from the Public Health Service (PHS) Commissioned Corps.  He is a recipient of the Merck Presidential Fellowship Award, and has received several PHS Unit Commendations, as well as PHS Meritorious Service, Commendation, and Achievement Awards, and CDER and FDA awards for excellence in laboratory research.  He earned his BS in Pharmacy from the University of Rhode Island, his Ph.D. in Pharmacology at the University of Virginia, and was awarded a postdoctoral PRAT Fellowship at the National Institutes of Health.  He has served as President of the Regulatory and Safety Evaluation Specialty Section of the Society of Toxicology, as Co-Director of the Critical Path Institute's Predictive Safety Testing Consortium (PSTC), as Co-Chair of the PSTC Nephrotoxicity Biomarker Working Group, and currently serves as Rapporteur of the International Conference on Harmonization S1 Carcinogenicity Expert Working Group, Chairperson of the PhRMA Clinical and Preclinical Development Committee's Carcinogenicity Key Issue Working Group, and Chairperson of the FNIH Biomarker Consortium's Clinical Kidney Safety Biomarker Qualification Project Team.

Day Two

Tuesday, August 29, 2017

15:30 | Panel Discussion: Where the Rubber Meets the Road, the Roadmap to Regulatory Acceptance

08.30 | Integrating Advanced In Vitro Liver Models with Other New Technologies to Reduce Risks of Drug Induced Liver Injury (DILI) in Pharmaceutical Development

Kristin Fabre
Microphysiological Systems Development & Implementation Lead
AstraZeneca

Dr. Fabre is joining the Drug Safety and Metabolism team at AstraZeneca as the Microphysiological Systems Development and Implementation Lead, working with several key AZ members to develop how to best utilize MPS technology for drug development and screening.  Prior to joining AZ, she was the Scientific Program Manager for the Microphysiological Systems (or Organs-on-Chips) Initiative at NIH National Center for Advancing Translational Sciences (NCATS).  This role included providing oversight on all MPS cooperative agreements, including members from FDA, DARPA, NIH and several academic institutions across the United States in addition to building public-private partnerships. Dr. Fabre received her BS in Biology from the University of Wyoming, followed by her MS and PhD from Colorado State University in Cell and Molecular Biology.  Prior to joining NCATS, she was at the NIH National Cancer Institute as a postdoctoral fellow in the Radiation Biology Branch.  During her time at the NCI, Dr. Fabre was highly involved with training programs and was Chair of the NCI Fellows and Young Investigators Steering Committee and created the NCI Fellows Outreach Committee.

Day One

Monday, August 28, 2017

09.30 | Pharma Insight Panel: Innovation, Adoption, Implementation. Overcoming Barriers to Entry for Pharma

09.00 | Implementing Microphysiological Systems into AstraZeneca’s Research Projects

Matthew Wagoner
Associate Director of Mechanistic and Investigative Toxicology
Takeda

Matt Wagoner leads the Global Investigatory Toxicology network for Takeda Pharmaceuticals, where their team applys microphysiological systems (MPS) as predictive and mechanistic toxicology tools in support of discovery-phase projects.  Before Takeda, Matt led the mRNA safety strategy for AstraZeneca Pharmaceuticals, and worked to develop and deploy MPS tools in support of projects. Matt has his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and bachelors in biochemistry from the University of Illinois Urbana Champaign.

Day Two

Tuesday, August 29, 2017

09.00 | Scientific Supermodels: Integrating Microphysiological & Mathematical Models to Improve Translation to Clinic

Brian Berridge
Director & Head WW Animal Research Strategy
GSK

Brian Berridge is a Senior GSK Fellow and Head of WW Animal Research Strategy at GlaxoSmithKline.  He is a veterinarian with residency and PhD training from Texas A&M University, a Diplomate of the American College of Veterinary Pathologists and a visiting instructor at the University of North Carolina where he teaches cardiovascular toxicology.  He is a member of the Executive Board and Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee.  He is a member of the Scientific Advisory Committee for the Advancement of Alternative Toxicological Methods for NIEHS and leads the IQ Microphysiological Systems Working Group.

Day One

Monday, August 28, 2017

09.30 | Pharma Insight Panel: Innovation, Adoption, Implementation. Overcoming Barriers to Entry for Pharma

08:30 | Precompetitive Partnerships For Implementing MPS – IQ Consortium Update

07:00 | Welcoming Remarks

Adrian Roth
Head of Mechanistic Safety
Hoffman La Roche

Adrian Roth is heading the Mechanistic Safety Section within Roche’s Pharmaceutical Sciences organization at the Roche Innovation Centre in Basel, Switzerland. His group has established a series of novel tools to experimentally address safety issues arising during all stages of drug development. The main focus is selection and prioritization of drug candidates early on in development before clinical candidate selection, as well as de-risking by mechanistic understanding in later stage drug development programs up to clinical phases. This is done by use of human primary & stem cell based or complex 3D models as well as technologies for analysis such as High content imaging, Genomics and others. Applying such tools, new and innovative approaches could be established in to support key programs with challenging issues and also included interaction with regulatory bodies. By partnering with project teams, Adrian’s group develops strategies for lean development of safe drugs by integration of science-based concepts arising from sate of the art experimental work. Adrian Roth holds a master in molecular biology and biochemistry and a PhD  in Neuroscience. He was a postdoctoral fellow at the Biocentre of the University of Basel in the group of Urs A. Meyer, where he studied transcriptional regulation of P450s by nuclear receptors.  In 2006, Adrian Roth joined Hoffmann-La Roche to lead a laboratory in the field of Toxicogenomics followed by different roles until he became Head of Mechanistic Safety. Since 2014, Adrian Roth is also Associate Professor at the Faculty of Sciences from the University of Basel.

Day One

Monday, August 28, 2017

09.30 | Pharma Insight Panel: Innovation, Adoption, Implementation. Overcoming Barriers to Entry for Pharma

Day Two

Tuesday, August 29, 2017

13:00 | Bioprinted 3D Primary Liver Tissues Enabling the Assessment of Organ-Level Responses to Clinical Drug Induced Toxicity In Vitro

Linda Griffith
Professor of Biological Engineering & Mechanical Engineering, Director of the MIT Physiomimetics Program
MIT

Prof. Linda G. Griffith received a Bachelor's Degree from Georgia Tech and a PhD degree from the University of California at Berkeley, both in chemical engineering. Griffith’s is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship, the Popular Science Brilliant 10 Award, NSF Presidential Young Investigator Award, the MIT Class of 1960 Teaching Innovation Award, Radcliffe Fellow and several awards from professional societies. Prof. Linda G. Griffith received a Bachelor's Degree from Georgia Tech and a PhD degree from the University of California at Berkeley, both in chemical engineering. Griffith’s is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship, the Popular Science Brilliant 10 Award, NSF Presidential Young Investigator Award, the MIT Class of 1960 Teaching Innovation Award, Radcliffe Fellow and several awards from professional societies.

Day One

Monday, August 28, 2017

16:40 | Marrying Systems Biology with Tissue Engineering for MPS Disease Modeling

12.15 | Panel Discussion: Development of Complex In Vitro Models for Preclinical Efficacy Testing

John Wikswo
Gordon A. Cain University Professor & Director
VIIBRE

John Wikswo is a university professor at Vanderbilt University and the founding director of the Vanderbilt Institute for Integrative Biosystems Research and Education. His work on organs-on-chips focuses on the neurovascular unit, cardiac tissue, and automated devices for perfusion, control, interrogation, and interconnection of organ chips.

Workshop A

Wednesday, August 30, 2017

09:00 |
Organs-on-chips: A Developer’s Masterclass

Day One

Monday, August 28, 2017

12.15 | Panel Discussion: Development of Complex In Vitro Models for Preclinical Efficacy Testing

Day Two

Tuesday, August 29, 2017

13:30 | Hormonal Modulation of Organs-on-Chips to Recapitulate In Vivo ADME Tox Profiles In Vitro

Jason Ekert
Head Complex In-Vitro Models
GSK

Dr. Jason Ekert is Head of Complex In Vitro Models in the R&D Platform Technology & Sciences organization at GlaxoSmithKline.  Dr Ekert leads an integrated enterprise strategy for sustained, portfolio driven growth in R&D application of complex human-relevant and translatable complex in vitro models. Dr Ekert’s group drives the coordination and prioritization of development and integrated use of complex in vitro technologies for efficacy, safety and biometabolism studies. Dr Ekert received his PhD in Medical Science from Adelaide University in Australia. He performed post-doctoral training at the University of California, Davis and Coriell Institute for Medical Research. Before coming to GSK Dr Ekert worked for 11 years at Janssen BioThereapeutics in early biotherapeutic drug discovery in target discovery, drug validation and mechanism of action studies applying 3D cell cultures, induced pluripotent stem cells and primary cells in complex cell-based assays across multiple therapeutic areas. His current focus at GSK is to improve predictive validity of early preclinical models leading to better characterized molecules, decreased R&D cycle time and a reduction in attrition.

Day One

Monday, August 28, 2017

12.15 | Panel Discussion: Development of Complex In Vitro Models for Preclinical Efficacy Testing

11.15 | Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing

Esmaiel Jabbari
Professor of Chemical & Biomedical Engineering
University of South Carolina

Dr. Jabbari is a Tenured Full Professor of Chemical and Biomedical Engineering and the Director of Biomaterials, Tissue Engineering and Drug Delivery at the University of South Carolina. He earned his Ph.D. from Purdue University in Chemical Engineering. He began his independent career as an Assistant Professor in the Departments of Biomedical Engineering and Orthopedic Research at Mayo Clinic upon completion of his post-doctoral training at Monsanto and Rice University. Jabbari’s research is focused on engineering 3D multi-cellular co-culture systems to study and the effect of factors in the microenvironment on function and fate of stem cells in tissue regeneration and cancer therapy. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of AIMBE in 2013. He has published >250 books, book chapters, refereed journal articles (107 peer-reviewed), and conference proceedings, and presented >260 seminars at national and international conferences (67 plenary, keynote, and invited seminars). He serves as the Academic Editor for PLOS ONE. He is a member of numerous scientific organizations including AIChE, BMES, ACS, EMBS, SFB, TERMIS, MRS, ACS, and AACR.

Day One

Monday, August 28, 2017

11.45 | A 3D Cancer Stem Cell Tissue Model for Drug Screening

Shane Horman
Research Investigator III
Novartis GNF

Dr. Shane Horman runs the Advanced Assay group at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. His group is dedicated to the development and implementation of complex and 3D high content screening platforms that may better reflect in vivo patient biology for early stage drug discovery.

Day One

Monday, August 28, 2017

14:30 | Industrialized 3D Drug Discovery: Spheroids in 1536-well Format

Sylvia Goldoni
Investigator II
Novartis IBR

Day One

Monday, August 28, 2017

15:10 | Drug profiling in an Immune Cell-Tumor Spheroid Co-Culture Model

Joseph Charest
Program Manager, Human Organ Systems
Draper

Dr. Charest is a Program Manager for Draper’s Human Organ Systems where he directs efforts to build systems which recapitulate human organ function.  The systems are in vitro models of human tissue which exhibit the function of native organs and can be used to screen effects of drugs and other therapies on those organs.  His teams leverage micro/nano-fabrication, microfluidics, and advanced machining techniques to create systems to coax cells into forming functional tissue with the end result speeding development of therapies to better treat patients.  Dr. Charest graduated from Georgia Tech with an MS and PhD in Mechanical Engineering and from Penn State Honors College with a BS in Mechanical Engineering and has worked at Bell Labs/Lucent Technologies, Sandia National Labs, and several startups/spinouts.

Day One

Monday, August 28, 2017

14:00 | Leveraging Microfabrication for Tissue Models with a Path to Validation

Sharon Presnell
CSO
Organovo

Day One

Monday, August 28, 2017

16:10 | Tissue-level Modeling of Chronic Liver Injury & Disease

Jonathan Himmelfarb
Professor of Medicine & Director
Kidney Research Institute University of Washington

Dr. Jonathan Himmelfarb is Professor of Medicine, Director of the Kidney Research Institute, and also holds the Joseph W. Eschbach, M.D. Endowed Chair in Kidney Research at the University of Washington (UW) School of Medicine.  Dr. Himmelfarb has been a leader in clinical and translational research focused on kidney disease for over two decades. Dr. Himmelfarb has served on numerous grant review committees, Scientific Advisory Boards and has held leadership positions in many national and international nephrology societies.  He is a former President of the American Society of Nephrology.  Dr. Himmelfarb has been a member of the ABIM Subspecialty Board on Nephrology, an Associate Editor of the Journal of the American Society of Nephrology, and has served on the Editorial Boards of the Journal of the American Society of Nephrology, Clinical Journal of the American Society of Nephrology, Kidney International and BMC Medicine, the Faculty of 1,000 in Medicine, and is a founding member of the Faculty of 1000 in Research.  He has served on expert panels for the U.S. Food and Drug Administration, Veterans Health Administration, Centers for Medicare & Medicaid Services and other organizations. He is Chair of the External Advisory Committee for the University of Texas Southwestern and Duke University O'Brien Centers.  Dr Himmelfarb is the author of more than 250 peer-reviewed publications.

Day One

Monday, August 28, 2017

17:20 | Enhancing Human Kidney on Chips for Disease Modeling & Toxicity Testing

J. Eric McDuffie
Scientific Director, Head of Investigative & Mechanistic Toxicology
Janssen Pharmaceuticals

Day Two

Tuesday, August 29, 2017

15:30 | Panel Discussion: Where the Rubber Meets the Road, the Roadmap to Regulatory Acceptance

09.40 | Microphysiological Models Informing Target Assessment to Translational Biomarkers

Armando Lagrutta
Director, Cellular Electrophysiology & Pharmacology, Safety Assessment & Laboratory Animal Resources
Merck and Co. Inc.

Armando Lagrutta is Director of Cellular Electrophysiology and Pharmacology, Safety and Exploratory Pharmacology department, in the preclinical safety assessment area at Merck Research Laboratories, Merck & Co., Inc., West-Point/PA.  His primary research interests are in vitro safety pharmacology with a focus on cardiovascular ion channels profiling, evaluation and implementation of novel assays using human induced pluripotent stem-cell-derived cardiomyocytes. In general, Armando and his team are developing and implementing novel in vitro technologies, and investigating novel therapeutic targets and mechanism(s) involving different ion channels interacting more particularly with Ca2+ handling mechanisms and responsible for cardiac adverse reactions.  Armando is first author of n=13 peer‑reviewed or invited review articles, and co-author of n=28 additional publications. He has worked in the pharmaceutical industry, at Merck & Co., for 21 years, in the areas of drug discovery and preclinical safety assessment. He received his Ph.D. in Cell Biology with a concentration in Developmental Biology at the University of Connecticut. He conducted postdoctoral fellowships at Emory University School of Medicine, and the Vollum Institute for Advanced Biomedical Research, Oregon Health Science University.

Day Two

Tuesday, August 29, 2017

11:20 | A New Comprehensive Translational Paradigm Using Human iPSCDerived Cardiomyocytes for Safety Assessment of Drug-Induced Arrhythmias

Shuo Xiao
Assistant Professor Reproductive Health & Toxicology
University of South Carolina

Dr. Shuo Xiao is the Principal Investigator in Reproductive Health & Toxicology Laboratory in University of South Carolina. By using both in vitro and in vivo models, his research interest is primarily focusing on how xenobiotics adversely affect the female reproductive function and fertility and how to use the microfluidic technology and 3D tissue culture methods to screen and test compounds’ reproductive toxicity.

Day Two

Tuesday, August 29, 2017

14:00 | Using Microfluidic Technology & a 3D In Vitro Follicle Growth Model to Test Compounds’ Female Reproductive Toxicity

Lucie Low
Tissue Chip Program Manager
NIH/NCATS

Dr. Low obtained her PhD and MSc in Neuroscience from University College London, UK, after studying an undergraduate degree in Physiology with Psychology at Magdalen College, Oxford University, UK.   She completed postdoctoral research  Fellowships at McGill University (Montreal, Canada) and the National Center for Complementary and Integrative Health (NCCIH) at NIH in Bethesda, MD, USA. She joined the National Center for Advancing Translational Sciences as the Tissue Chip Program Manager in 2016.

Day Two

Tuesday, August 29, 2017

15:30 | Panel Discussion: Where the Rubber Meets the Road, the Roadmap to Regulatory Acceptance

15:00 | The NIH Program on Tissues-on-Chips for Drug Screening, Safety & Efficacy Testing: Progress & Future Plans

Murat Cirit
Director, Translational Systems Pharmacology
MIT

Murat Cirit, PhD, is the director of the Translational Systems Pharmacology Team and System Integration Task in the DARPA-PhysioMimetics program (“Human Physiome on a Chip”). MIT and various institutions collaborate in creating a platform that supports ten interacting micro-physiological systems (MPS). Murat completed his PhD at NCSU focusing on systems biology of growth factor-mediated signal transduction pathways. After completion of his PhD, he worked in the pharmaceutical industry focusing on preclinical drug discovery for oncology. He brings an interdisciplinary and systematic approach through his extensive experimental knowledge and computational modeling with an understanding of biological, physiological, and physical processes. His main research experience is systems pharmacology, systems biology, applied tissue engineering, cell biology and signal transduction networks. His current focus as the scientific lead is integrating various scientific fields to build interacting MPSs by interfacing platform engineering & tissue engineering for pharmacology studies.

Workshop B

Wednesday, August 30, 2017

13:00 |
Translational & Quantitative Systems Modeling (QSP) to Enhance 3D MPS Model Insights

Day Two

Tuesday, August 29, 2017

15:30 | Panel Discussion: Where the Rubber Meets the Road, the Roadmap to Regulatory Acceptance

Henning Mann
Senior Scientist
Nortis Inc

Dr. Mann earned his PhD in physiological chemistry studying protein-protein and cell-protein interactions in the extracellular matrix. As a postdoctoral fellow he worked at the Fred Hutchinson Cancer Research Center in Seattle, WA, where he focused on understanding the expression, function and interactions of the immunostimulatory receptor-ligand pairs MIC and NKG2D. He then worked as Senior Staff Scientist at Seattle Biomed on developing and understanding in vitro culture assays for Plasmodium falciparum in perfused extracellular matrix microenvironments before joining Nortis, Inc. in 2012. As a Senior Research Scientist at Nortis, Dr. Mann leads the company's angiogenesis, vascularized tumor and immuno-oncology efforts.

Day One

Monday, August 28, 2017

15:00 | Nortis' microfluidic Organ-on-Chip Technology in Research and Preclinical Drug Testing on Human Tissue Microenvironments (TME)

Fabian Zanella
Director of R&D
StemoniX

Fabian Zanella’s scientific expertise is focused on cell-based assay development, and applications of human induced pluripotent stem cells (hiPSCs)-derived cells in drug screening and disease modelling. Fabian joined the core founding team StemoniX as their first employee and has been directly involved in steering the R&D activities at StemoniX in the design, validation and implementation of high throughput physiologically relevant screening platforms involving hiPSC-derived cardiomyocytes and hiPSC-derived cells from the neuronal lineage.

Day Two

Tuesday, August 29, 2017

11.10 | MicroHeart: A Screening-Ready, Physiologically Relevant Human iPSC-Derived Cardiomyocyte Platform.

B. Prabhakar Pandian
Chief Technology Officer
SynVivo Inc.

Day One

Monday, August 28, 2017

17:10 | Physiologically Relevant 3D Tissue Models for Translational Studies

Misti Ushio, Ph.D.
CEO
TARA Biosystems

Misti Ushio, PhD. is the founding CEO of TARA Biosystems.  Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she advised and invested in life science companies to help them translate their transformational science into commercially successful companies. Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios. She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).  She also serves as a Director on the Boards of private and public life science companies.

Day Two

Tuesday, August 29, 2017

11.50 | iPSC Derived Mature Cardiac Tissue for Drug Development

Matthew R. Gevaert
Chief Executive Officer
KIYATEC Inc.

Dr. Matthew (Matt) Gevaert is the CEO of KIYATEC Inc., a complementary cancer diagnostics company pioneering methods to accurately predict individual cancer patients’ response to drugs through translational application of advanced 3D cell culture technology.  Gevaert’s background combines both business and technology; before co-founding KIYATEC he led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio and has previous experience with Merck, 3M and Dow Chemical.  Gevaert holds a bachelor’s degree in Chemistry from the University of Waterloo and a doctorate in Bioengineering from Clemson University.  He maintains current appointments as adjunct professor in the Clemson University Department of Bioengineering and as a lecturer in the Clemson MBA in Entrepreneurship & Innovation.

Day Two

Tuesday, August 29, 2017

09.30 | Translatable Discoveries Bridging the In Vitro In Vivo Gap